Table 1

Baseline patient characteristics by vaccination status

Vaccination status

Baseline characteristics, n (%)

Vaccinated

n = 551

Unvaccinated

n = 43,564


Age groups (years)

50 to 59

202 (36.7)

30,156 (69.2)

60 to 64

275 (49.9)

9,573 (22.0)

65 and older

74 (13.4)

3,835 (8.8)

Women

352 (63.9)

27,091 (62.2)

Inflammatory/Autoimmune disease

RA

206 (37.4)

19,120 (43.9)

Psoriatic arthritis

11 (2.0)

856 (2.0)

Psoriasis

146 (26.5)

10,566 (24.3)

Inflammatory bowel diseases

136 (24.7)

8,503 (19.5)

Ankylosing spondylitis

8 (1.5)

625 (1.4)

Multiple diseases

44 (8.0)

3,894 (8.9)

Medicationsa

TNF antagonists user

27 (4.9)

4,186 (9.6)

Other biologics user

0 (0)

198 (0.5)

Conventional DMARDs user

92 (16.7)

9,312 (21.4)

Oral glucocorticoidsb

None

456 (82.8)

34,267 (78.7)

Low

86 (15.6)

8,041 (18.5)

Medium

7 (1.3)

902 (2.1)

High

2 (0.4)

354 (0.8)

Charlson comorbidity index

0

287 (52.1)

19,971 (45.8)

1

181 (32.9)

16,565 (38.0)

≥ 2

83 (15.1)

7,028 (16.1)

Inpatient hospitalization

No

466 (84.6)

36,158 (83.0)

Yes

45 (15.4)

7,406 (17.0)

Number of outpatient physician visits

0-2

83 (15.1)

8,705 (20.0)

3-5

227 (41.2)

16,843 (38.7)

6-10

185 (33.6)

13,376 (30.7)

11 and more

54 (9.8)

4,642 (10.7)


DMARDS, Disease-modifying antirheumatic drugs; RA, rheumatoid arthritis; TNF, tumor necrosis factor. aMeasured in the 6-month baseline period before the start of observation

bCumulative average daily prednisone-equivalent glucocorticoid dose in the past 183 days: none, low (< 10 mg/day), medium (10-20 mg/day), and high (> 20 mg/day).

Zhang et al. Arthritis Research & Therapy 2011 13:R174   doi:10.1186/ar3497

Open Data